Search

everythinglearnresearchcommunity

for

Search:↓

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

A woman's complete hair loss condition improved after recovering from COVID-19.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Tofacitinib may help treat nail dystrophy, especially when other treatments fail.

Olumiant should be covered for severe alopecia areata if certain conditions are met.

Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.

Several treatments are effective for pigmentary disorders like vitiligo and melasma.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.

Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.

Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.

Higher PD-1 levels are linked to fewer immune cells in hair follicles in alopecia areata.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.

Topical immunotherapy can treat alopecia areata, but its effectiveness varies and the exact mechanism is unclear.

Intramuscular triamcinolone acetonide is an effective treatment for severe alopecia areata, especially in males.

Phototherapy can help treat hair loss in alopecia areata.

The compound 16 from the Merremia peltata plant could potentially be a good treatment for hair loss (alopecia) due to its strong activity and favorable skin absorption.

High levels of IL6 and CRP, and low levels of vitamin D, might be indicators of alopecia areata.

Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.

People with moderate hair loss from Alopecia Areata feel more impacted than those with no or almost complete hair loss, and are more likely to seek treatment.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.

Androgenetic alopecia, a genetic disorder affecting up to 50% of adults, is caused by an excessive response to androgens leading to hair follicle shrinkage. Treatments include FDA-approved drugs, other therapies like low-dose oral minoxidil, and hair transplantation.

Alopecia areata causes a significant economic burden in Japan, mainly due to productivity loss.

Treating stubborn hair loss involves both medical and emotional support options.

Nanoparticles with specific drugs can help regrow hair in alopecia areata.

Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.